NCT00752856View on ClinicalTrials.gov

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 26, 2008

Primary Completion Date

May 5, 2011

Study Completion Date

February 11, 2014

Conditions
HIV Infections
Interventions
DRUG

Kaletra + Isentress

kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day

DRUG

Atripla

Atripla 1 tab once a day

Trial Locations (6)

90033

University Southern California, Los Angeles

90502

Harbor-UCLA, Torrance

90813

Living Hope Clinical Foundation, Long Beach

92103

University California San Diego, San Diego

92262

Desert AIDS Project, Palm Springs

92868

Univerisity California Irvine, Orange

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

California HIV/AIDS Research Program

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Abbott

INDUSTRY

lead

University of California, San Diego

OTHER